1. Adler U, Kruger S, Teut M, Ludtke R, Schutzler L, Martins F, Willich S, Linde K, Witt C. Homeopathy for depression: a randomized, partially double-blind, placebo-controlled, four-armed study (DEP- HOM). PloS one. 2013;81-9.
2. Akhondzadeh S, Tahmacebi-Pour N, Noorbala A, Amini H, Fallah-Pour H, Jamshidi A, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy research : PTR. 2005;19:148-151.
3. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology. 2012;15:589-600.
4. Amsterdam J. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Journal of Clinical Psychiatry. 2003;64:208-214.
5. Amsterdam J, Brunswick D, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--A putative, new antidepressant. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2002;26:1333-1338.
6. Arana G, Santos A, Laraia M, McLeod Bryant S, Beale M, Rames L, Roberts J, Dias J, Molloy M.
Dexamethasone for the treatment of depression: A randomized, placebo-controlled, double- blind trial. The American journal of psychiatry. 1995;152:265-267.
7. Asnis G, Bose A, Gommoll C, Chen C, Greenberg W. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double- blind, placebo-controlled study. Journal of Clinical Psychiatry. 2013;74:242-248.
8. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg W, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double- blind, fixed-dose, placebo-controlled study. Journal of Psychiatry and Neuroscience. 2014;39:40- 49.
9. Baldwin D, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine- referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology. 2012;22:482-491.
10. Bielski R, Cunningham L, Horrigan J, Londborg P, Smith W, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. Journal of Clinical Psychiatry. 2008;69:571-577.
11. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. The American journal of psychiatry. 2008;165:617-620.
12. Bjerkenstedt L, Edman G, Alken R, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression. A randomized, placebo controlled multi-center study in outpatients.
European archives of psychiatry and clinical neuroscience. 2005;255:40-47.
13. Bodkin J, Amsterdam J. Transdermal selegiline in major depression: A double-blind, placebo- controlled, parallel-group study in outpatients. The American journal of psychiatry.
2002;159:1869-1875.
14. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. Journal of Affective Disorders.
2011;128:83-94.
15. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2008;16:14-20.
16. Boulenger J, Loft H, Olsen C. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. International clinical
psychopharmacology. 2014;29:138-149.
17. Boyer P, Montgomery S, Lepola U, Germain J, Brisard C, Ganguly R, Padmanabhan S, Tourian K.
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International clinical psychopharmacology.
2008;23:243-253.
18. Bremner J. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.
Journal of Clinical Psychiatry. 1995;56:519-525.
19. Burke W, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry. 2002;63:331-336.
20. Claghorn J, Lesem M. A double-blind placebo-controlled study of Org 3770 in depressed outpatients.
Journal of Affective Disorders. 1995;34:165-171.
21. Clayton A, Croft H, Horrigan J, Wightman D, Krishen A, Richard N, Modell J. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry.
2006;67:736-746.
22. Clayton A, Kornstein S, Dunlop B, Focht K, Musgnung J, Ramey T, Bao W, Ninan P. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. The Journal of clinical psychiatry.
2013;74:1010-1017. Two studies included.
23. Clayton A, Tourian K, Focht K, Hwang E, Cheng R, Thase M. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
The Journal of clinical psychiatry. 2014;In press.
24. Clayton A, Zajecka J, Ferguson J, Filipiak-Reisner J, Brown M, Schwartz G. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International clinical psychopharmacology. 2003;18:151-156.
25. Cohn C, Robinson D, Roberts D, Schwiderski U, O'Brien K, Ieni J. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression. Journal of Clinical Psychiatry. 1996;57:15-18.
26. Coleman C, King B, Bolden-Watson C, Book M, Segraves R, Richard N, Ascher J, Batey S, Jamerson B, Metz A. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clinical Therapeutics. 2001;23:1040-1058.
27. Corrigan M, Denahan A, Wright C, Ragual R, Evans D. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and anxiety. 2000;11:58-65.
28. Costa e Silva J, Ruschel S, Caetano D, Rocha F, da Silva Lippi J, Arruda S, Ozun M. Placebo-controlled study of tianeptine in major depressive episodes. Pharmacopsychiatry. 1997;35:24-39.
29. Croft H, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. 2014;75:e1291-1298.
30. Croft H, Settle E, Houser T, Batey S, Donahue R, Ascher J. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clinical Therapeutics. 1999;21:643-658.
31. Cunningham L. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Annals of Clinical Psychiatry. 1997;9:157-164.
32. Cutler A, Montgomery S, Feifel D, Lazarus A, Astrom M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
The Journal of clinical psychiatry. 2009;70:526-539.
33. DeMartinis N, Yeung P, Entsuah R, Manley A. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. The Journal of clinical psychiatry. 2007;68:677-688.
34. Detke M, Lu Y, Goldstein D, Hayes J, Demitrack M. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry.
2002;63:308-315.
35. Detke M, Lu Y, Goldstein D, McNamara R, Demitrack M. Duloxetine 60 mg once daily dosing versus placebo in the actue treatment of major depression. Journal of psychiatric research.
2002;36:383-390.
36. Detke M, Wiltse C, Mallinckrodt C, McNamara R, Demitrack M, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial.
European Neuropsychopharmacology. 2004;14:457-470.
37. Dube S, Dellva M, Jones M, Kielbasa W, Padich R, Saha A, Rao P. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res. 2010;44:356-363.
38. Dunlop B, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia C. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. Journal of clinical psychopharmacology. 2011;31:569-576.
39. Fabre L, Abuzzahab F, Amin M, Claghorn J, Mendels J, Petrie W, Dube S, Small J. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biological psychiatry. 1995;38:592-602.
40. Fava M, Alpert J, Nierenberg A, Mischoulon D, Otto M, Zajecka J, Murck H, Rosenbaum J. A double- blind, randomized trial of St. John's Wort, fluoxetine, and placebo in major depressive disorder.
Journal of clinical psychopharmacology. 2005;25:441-447.
41. Fava M, Amsterdam J, Deltito J, Salzman C, Schwaller M, Dunner D. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Annals of Clinical Psychiatry. 1998;10:145-150.
42. Feiger A. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacology bulletin. 1996;32:659-665.
43. Feiger A, Heiser J, Shrivastava R, Weiss K, Smith W, Sitsen J, Gibertini M. Gepirone extended-release:
New evidence for efficacy in the treatment of major depressive disorder. Journal of Clinical Psychiatry. 2003;64:243-249.
44. Feiger A, Rickels K, Rynn M, Zimbroff D, Robinson D. Selegiline transdermal system for the treatment of major depressive disorder: An 8-week, double-blind, placebo-controlled, flexible-dose
titration trial. Journal of Clinical Psychiatry. 2006;67:1354-1361.
45. Feiger A, Tourian K, Rosas G, Padmanabhan S. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.
CNS Spectr. 2009;14:41-50.
46. Feighner J, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to- severe depression. Journal of Clinical Psychiatry. 1999;60:824-830.
47. Ferguson J, Wesnes K, Schwartz G. Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. International clinical psychopharmacology. 2003;18:9-14.
48. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A double-blind,
randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. 2006;39:66-75.
49. Gillin J, Lauriello J, Kelsoe J, Rapaport M, Golshan S, Kenny W, Sutton L. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry research. 1995;58:99-105.
50. Golden R, Nemeroff C, McSorley P, Pitts C, Dube E. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Journal of Clinical Psychiatry.
2002;63:577-584.
51. Goldstein D, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack M. Duloxetine in the treatment of depression. A double-blind placebo-controlled comparison with paroxetine. Journal of clinical psychopharmacology. 2004;24:389-399.
52. Goldstein D, Mallinckrodt C, Lu Y, Demitrack M. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. Journal of Clinical Psychiatry. 2002;63:225-231.
53. Gommoll C, Greenberg W, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER 940-120 mg/day) in patients with major depressive disorder. Journal of Drug Assessment. 2014;3:10-19.
54. Griebel G, Beeske S, Stahl S. The vasopression V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. The Journal of Clinical Psychiatry. 2012;73:1403-1411. Three studies included.
55. Group HDTS. Effect of hypericum perforatum (St. John's Wort) in major depressive disorder. A randomized controlled trial. JAMA. 2002;287:1807-1814.
56. Halikas J. Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients. Human psychopharmacology. 1995;10:S125-S133.
57. Henigsberg N, Mahableshwarkar A, Jacobsen P, Chen Y, Thase M. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. The Journal of clinical psychiatry. 2012;73:953-959.
58. Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. The Journal of clinical psychiatry. 2013;74:587-594.
59. Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R, Gee M, Wightman D, O'Leary M, Millen L, Leon M, Briggs M, Krishen A, Modell J. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. Journal of psychopharmacology. 2010;24:521-529.
60. Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M, Modell J. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of psychopharmacology.
2009;23:531-538.
61. Hewett K, Gee M, Krishen A, Wunderlich H, Le Clus A, Evoniuk G, Modell J. Double-blind, placebo- controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of psychopharmacology. 2010;24:1209-1216.
62. Higuchi T, Hong J, Jung H, Watanabe Y, Kunitomi T, Kamijima K. Paroxetine controlled-release
formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo- controlled study in Japan and Korea. Psychiatry and clinical neurosciences. 2011;65:655-663.
63. Inamdar A, Merlo-Pich E, Gee M, Makumi C, Mistry P, Robertson J, Steinberg E, Zamuner S, Learned S, Alexander R, Ratti E. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo- controlled, double-blind, multicentre studies using a Bayesian approach. Journal of
psychopharmacology. 2014;28:570-581. Two studies included.
64. Iwata N, Tourian K, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. Journal of psychiatric practice. 2013;19:5-14.
65. Jain R, Mahableshwarkar A, Jacobsen P, Chen Y, Thase M. A randomized, double-blind, placebo- controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2012;16:313-321.
66. Kalb R, Trautmann-Sponsel R, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. Pharmacopsychiatry. 2001;34:96-103.
67. Kasper S, Anghelescu I, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC medicine. 2006;4:14.
68. Kasper S, de Swart H, Andersen H. Escitalopram in the treatment of depressed elderly patients. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2005;13:884-891.
69. Kasper S, Moller H, Montgomery S, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. International clinical psychopharmacology. 1995;9:3-12.
70. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C. Randomized, double- blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry.
2013;21:769-784.
71. Katona C, Hansen T, Olsen C. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International clinical psychopharmacology. 2012;27:215-223.
72. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist
aprepitant in the treatment of major depressive disorder. Biological psychiatry. 2006;59:216-223.
Five studies included.
73. Kennedy S, Avedisova A, Gimenez-Montesinos N, Belaidi C, de Bodinat C. A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25-50mg) in patients with major depressive disorder. European neuropsychopharmacology : the journal of the European College of
Neuropsychopharmacology. 2014;24:553-563.
74. Kennedy S, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology. 2006;16:93-100.
75. Khan A, Cutler A, Kajdasz D, Gallipoli S, Athanasiou M, Robinson D, Whalen H, Reed CR. A
randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. The Journal of clinical psychiatry. 2011;72:441- 447.
76. Khan M. A randomized, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Human psychopharmacology. 1995;10:S119-S1124.
77. Kornstein S, Jiang Q, Reddy S, Musgnung J, Guico-Pabia C. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and
postmenopausal women with major depressive disorder. The Journal of clinical psychiatry.
2010;71:1088-1096.
78. Koshino Y, Bahk W, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double- blind, placebo-controlled study in Asian patients. Neuropsychiatric disease and treatment.
2013;9:1273-1280.
79. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan K, Archer G, Modell J, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. Journal of psychopharmacology. 2012;26:653-662.
Two studies included.
80. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's Wort extract WS 5570 in major depression: A double-blind, placebo-controlled trial. The American journal of psychiatry.
2002;159:1361-1366.
81. Lepola U, Loft H, Reines E. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo- controlled study in depression in primary care. International clinical psychopharmacology.
2003;18:211-217.
82. Lieberman D, Montgomery S, Tourian K, Brisard C, Rosas G, Padmanabhan K, Germain J, Pitrosky B. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.
International clinical psychopharmacology. 2008;23:188-197.
83. Liebowitz M, Manley A, Padmanabhan S, Ganguly R, Tummala R, Tourian K. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Current medical research and opinion. 2008;24:1877-1890.
84. Liebowitz M, Tourian K, Hwang E, Mele L, Investigators S. A double-blind, randomized, placebo- controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC psychiatry. 2013;13:94.
85. Liebowitz M, Yeung P, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. The Journal of clinical psychiatry. 2007;68:1663-1672.
86. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-
controlled dose range study. International clinical psychopharmacology. 2002;17:239-247.
87. Lopresti A, Maes M, Maker G, Hood S, Drummond P. Curcumin for the treatment of major
depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368- 375.
88. Lydiard R, Stahl S, Hertzman M, Harrison W. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry. 1997;58:484-491.
89. Mahableshwarkar A, Jacobsen P, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Current medical research and opinion. 2013;29:217-226.
90. Mahableshwarkar A, Jacobsen P, Chen Y, Serenko M, Trivedi M. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology. 2015;In press.
91. Malt U, Robak O, Madsbu H, Bakke O, Loeb M. The Norweigian nautralistic treatment study of depression in general practice (NORDEP)--I: Randomised double blind study. Bmj.
1999;318:1180-1184.
92. Marangell L, Martinez J, Zboyan H, Kertz B, Kim H, Puryear L. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. The American journal of psychiatry. 2003;160:996-998.
93. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. International clinical psychopharmacology. 2015;30:67-74.
94. McIntyre R, Lophaven S, Olsen C. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2014;17:1557-1567.
95. Mendels J, Reimherr F, Marcus R, Roberts D, Francis R, Anton S. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Journal of Clinical Psychiatry. 1995;56 30-36.
96. Mischoulon D, Nierenberg A, Schettler P, Kinkead B, Fehling K, Martinson M, Rapaport M. A double- blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus
docosahexaenoic acid for depression. The Journal of clinical psychiatry. 2015;76:54-61.
97. Mischoulon D, Papakostas G, Dording C, Farabaugh A, Sonawalla S, Agoston A, Smith J, Beaumont E, Dahan L, Alpert J, Nierenberg A, Fava M. A double-blind, randomized controlled trial of ethyl- eicosapentaenoate for major depressive disorder. The Journal of clinical psychiatry.
2009;70:1636-1644.
98. Mischoulon D, Price L, Carpenter L, Tyrka A, Papakostas G, Baer L, Dording C, Clain A, Durham K, Walker R, Ludington E, Fava M. A double-blind, randomized, placebo-controlled clinical trial of S- adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. The Journal of clinical psychiatry. 2014;75:370-376.
99. Montgomery S, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo- controlled, proof-of-concept study. The Journal of clinical psychiatry. 2013;74:363-369.
100. Moreno R, Teng C, Almeida K, Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample.
Rev Bras Psiquiatr. 2006;28:29-32.
101. Moshiri E, Basti A, Noorbala A, Jamshidi A, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L.
(petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2006;13:607-611.
102. Nair N, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin N, Kragh-Sorensen P, Kuhn H, Leek C, Stage K. Moclobemide and nortriptyline in elderly depressed patients. A randomized,
multicentre trial against placebo. Journal of Affective Disorders. 1995;33:1-9.
103. Nations K, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, Gertsik L, Johnstone J, Lee A, Pande Y, Ruigt G, Ereshefsky L. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. Journal of psychopharmacology. 2012;26:1525-1539.
104. Nemeroff C, Schatzberg A, Goldstein D, Detke M, Mallinckrodt C, Lu Y, Tran P. Duloxetine for the treatment of major depressive disorder. Psychopharmacology bulletin. 2002;36:106-132. Six studies included.
105. Nemeroff C, Thase M. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Journal of psychiatric research. 2007;41:351-359.
106. Nierenberg A, Greist J, Mallinckrodt C, Prakash A, Sambunaris A, Tollefson G, Wohlreich M.
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current medical research and opinion. 2007;23:401-416.
107. Oakes T, Myers A, Marangell L, Ahl J, Prakash A, Thase M, Kornstein S. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Human psychopharmacology. 2012;27:47-56. Two studies included.
108. Olie J, Gunn K, Katz E. A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression. European psychiatry : the journal of the Association of European Psychiatrists. 1997;12:34-41.
109. Olie J, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. The international journal of
neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2007;10:661-673.
110. Pangallo B, Dellva M, D'Souza D, Essink B, Russell J, Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res. 2011;45:748-755.
111. Papakostas G, Vitolo O, Ishak W, Rapaport M, Zajecka J, Kinrys G, Mischoulon D, Lipkin S, Hails K, Abrams J, Ward S, Meisner A, Schoenfeld D, Shelton R, Winokur A, Okasha M, Bari M, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. The Journal of clinical psychiatry.
2012;73:1541-1547.
112. Perahia D, Wang F, Mallinckrodt C, Walker D, Detke M. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European psychiatry : the journal of the Association of European Psychiatrists. 2006;21:367-378.
113. Philipp M, Kohnen R, Hiller K. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. Bmj.
1999;319:1534-1539.
114. Rapaport M, Lydiard R, Pitts C, Schaefer D, Bartolic E, Iyengar M, Carfagno M, Lipschitz A. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo- controlled trial. The Journal of clinical psychiatry. 2009;70:46-57.
115. Rapaport M, Schneider L, Dunner D, Davies J, Pitts C. Efficacy of controlled-release paroxetine in the treatment of late-life depression. Journal of Clinical Psychiatry. 2003;64:1065-1074.
116. Raskin J, Wiltse C, Dinkel J, Walker D, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Journal of clinical
psychopharmacology. 2008;28:32-38.
117. Raskin J, Wiltse C, Siegal A, Sheikh J, Xu J, Dinkel J, Rotz B, Mohs R. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164:900-909.
118. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan K, Fernandes S. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. Journal of clinical psychopharmacology. 2011;31:727-733. Two studies included.
119. Reimherr F, Cunningham L, Batey S, Johnston J, Ascher J. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clinical Therapeutics. 1998;20:505-516.
120. Rickels K, Athanasiou M, Robinson D, Gibertini M, Whalen H, Reed C. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double- blind, placebo-controlled trial. The Journal of clinical psychiatry. 2009;70:326-333.
121. Rickels K, Derivan A, Kunz N, Pallay A, Schweizer E. Zalospirone in major depression: a placebo- controlled multicenter study. Journal of clinical psychopharmacology. 1996;16:212-217.
122. Riesenberg R, Rosenthal J, Moldauer L, Peterson C. Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin(R)) in subjects with major depressive disorder. Psychopharmacology. 2012;221:601-610.
123. Robinson M, Oakes T, Raskin J, Liu P, Shoemaker S, Nelson J. Acute and long-term treatment of late- life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry. 2014;22:34- 45.
124. Roose S, Sackeim H, Krishnan K, Pollock B, Alexopoulos G, Lavretsky H, Katz I, Hakkarainen H, Old- Old DSG. Antidepressant pharmacotherapy in the treatment of depression in the very old: A randomized, placebo-controlled trial. The American journal of psychiatry. 2004;161:2050-2059.
125. Rudolph R, Fabre L, Feighner J, Rickels K, Entsuah R, Derivan A. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry. 1998;59:116-122.
126. Rudolph R, Feiger A. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders. 1999;56:171-181.
127. Ruther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry.
1999;32:127-135.
128. Sambunaris A, Bose A, Gommoll C, Chen C, Greenberg W, Sheehan D. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. Journal of clinical psychopharmacology. 2014;34:47-56.
129. Sayyah M, Sayyah M, Kamalinejad M. A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of echium amoenum in the treatment of mild to moderate major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30:166-169.
130. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14:361-370.
131. Schneider L, Nelson J, Clary C, Newhouse P, Krishnan K, Shiovitz T, Weihs K, Group SEDS. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. The American journal of psychiatry. 2003;160:1277-1285.
132. Septien-Velez L, Pitrosky B, Padmanabhan S, Germain J, Tourian K. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. International clinical psychopharmacology. 2007;22:338-347.
133. Sheehan D, Croft H, Gossen E, Levitt R, Brulle C, Bouchard S, Rozova A. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry.
2009;6:20-33.
134. Shelton R, Keller M, Gelenberg A, Dunner D, Hirschfeld R, Thase M, Russell J, Lydiard R, Crits- Christoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl S, Hallbreich U.
Effectiveness of St. John's Wort in major depression. JAMA. 2001;285:1978-1986.
135. Sramek J, Jasinsky O, Chang S, Shu V, Kashkin K, Kennedy S, Sadd C, Cutler N. Pilot efficacy trial of ABT-200 in patients with major depressive disorder. Depression. 1994/1995;2:315-318.
136. Sramek J, Kashkin K, Jasinsky O, Kardatzke D, Kennedy S, Cutler N. Placebo-controlled study of ABT- 200 versus fluoxetine in the treatment of major depressive disorder. Depression 1995;3:199- 203.
137. Stahl S. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biological psychiatry. 2000;48:894-901.
138. Stahl S, Fava M, Trivedi M, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. The Journal of clinical psychiatry. 2010;71:616-626.
139. Stahl S, Kaiser L, Roeschen J, Keppel Hesselink J, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. The international journal of
neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 1998;1:11-18.
140. Su K, Huang S, Chiu C, Shen W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology. 2003;13:267-271.
141. Thase M. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. Journal of Clinical Psychiatry. 1997;58:393-398.
142. Tollefson G, Bosomworth J, Heiligenstein J, Potvin J, Holman S. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. International
psychogeriatrics / IPA. 1995;7:89-104.
143. Tourian K, Padmanabhan S, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31 Pt. 1:1405-1423.
144. Tran P, Skolnick P, Czobor P, Huang N, Bradshaw M, McKinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012;46:64-71.
145. Trivedi M, Pigott T, Perera P, Dillingham K, Carfagno M, Pitts C. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Journal of Clinical Psychiatry. 2004;65:1356-1364.
146. Uebelhack R, Gruenwald J, Graubaum H, Busch R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Advances in therapy. 2004;21:265-275.
147. Wade A, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International clinical
psychopharmacology. 2002;17:95-102.
148. Walczak D, Apter J, Halikas J, Borison R, Carman J, Post G, Patrick R, Cohn J, Cunningham L, Rittberg B, Preskorn S, Kang J, Wilcox C. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. Annals of Clinical Psychiatry. 1996;8:139- 151.
149. Wang G, McIntyre A, Earley W, Raines S, Eriksson H. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatric disease and treatment.
2014;10:201-216.
150. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H, Moonstone Study G. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double- blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299-313.
151. Wilcox C, Ferguson J, Dale J, Heiser J. A double-blind trial of low- and high-dose ranges of gepirone- ER compared with placebo in the treatment of depressed outpatients. Psychopharmacology bulletin. 1996;32:335-342.
152. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo- controlled trial. Journal of clinical psychopharmacology. 2010;30:135-144.
153. Zarate C, Singh J, Quiroz J, De Jesus G, Denicoff K, Luckenbaugh D, Manji H, Charney D. A double- blind, placebo-controlled study of memantine in the treatment of major depression. The American journal of psychiatry. 2006;163:153-155.
154. Zhang Z, Tan Q, Tong Y, Li Q, Kang W, Zhen X, Post R. The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. J Affect Disord. 2008;109:91- 97.
